Dexcom G8 CGM: Features, Release Date, and What to Expect
Everything you need to know about the next generation of continuous glucose monitoring.
Last Updated: July 2026
Quick Answer: The Dexcom G8 is Dexcom’s upcoming continuous glucose monitor (CGM). Based on information released by the company, it is expected to feature a significantly smaller sensor, adaptive sensing technology, a 15-day wear period, and enhanced connectivity. Although the G8 has not yet received FDA clearance, Dexcom has outlined several planned improvements that could make it one of its most advanced CGM systems to date.[1][3]
| Dexcom G8 at a Glance | Details |
|---|---|
| Status | In Development |
| Regulatory Status | Not FDA Cleared |
| Expected FDA Submission | 2027 |
| Expected Launch | Late 2027–Early 2028 |
| Sensor Size | ~50% smaller than G7 |
| Expected Wear Time | 15 days (planned) |
| Key Innovation | Adaptive sensing platform |
Specifications and timelines are based on Dexcom’s current public roadmap and remain subject to regulatory review and future product updates.
Key Takeaways
- Approximately 50% smaller than the Dexcom G7.
- New adaptive sensing technology designed to improve accuracy throughout the sensor’s wear period.
- Expected 15-day wear time, matching Dexcom’s new long-term platform standard.
- Built as a completely new hardware platform for future biosensing capabilities.
- FDA submission is expected in 2027, with commercial availability anticipated in late 2027 or early 2028, pending regulatory approval.
What Is the Dexcom G8?
The Dexcom G8 is the successor to the Dexcom G7. Like previous Dexcom CGMs, it continuously measures glucose levels in interstitial fluid and sends real-time readings to compatible smartphones, smartwatches, insulin pumps, and diabetes management apps.[1]
A CGM displays real-time glucose readings and trends throughout the day. If you’re unsure how your glucose readings compare with recommended target ranges, see our Blood Sugar Charts guide for normal glucose levels before and after meals.
While a CGM helps you monitor glucose in real time, our A1C Calculator can help estimate your average blood glucose and long-term glucose control from an HbA1c result.
Rather than simply shrinking the hardware, Dexcom says the G8 introduces an entirely new sensing platform that continuously adapts to the body’s environment during wear, with the goal of improving performance over the life of each sensor.[1][6]
What’s Confirmed vs. What’s Still Unknown
Dexcom has publicly shared several details about the upcoming G8, while other specifications remain subject to regulatory review and future announcements. The infographic below separates officially confirmed information from details that have not yet been confirmed.
Dexcom G8 New Features
Adaptive Sensing Technology
The headline feature of the G8 is its adaptive sensing platform.
Unlike previous generations that rely primarily on factory calibration, the G8 is designed to continuously optimize sensor performance after insertion.[1][6] Dexcom says this technology is intended to:
- Improve overall accuracy
- Reduce sensor variability
- Maintain consistent performance throughout the wear period
- Better adapt to differences between individual users[1]
Complete clinical accuracy data has not yet been published.[1]
Approximately 50% Smaller Sensor
Dexcom has confirmed the G8 sensor will be about half the size of the G7.[1][6]
The smaller profile may provide several practical advantages:
- More comfortable wear
- Lower profile under clothing
- Easier placement
- Better comfort during exercise
- Less adhesive covering the skin
For many CGM users, sensor size has been one of the most requested improvements.
15-Day Wear Time
Dexcom has indicated that 15 days will become the standard wear duration for its next-generation CGM platform.[1][3]
Compared with a 10-day sensor, a 15-day wear period means:
- Fewer sensor changes each year
- Lower supply usage
- Greater convenience
- Less interruption to daily routines
Final wear specifications will be confirmed after regulatory review.[1]
Improved Connectivity
Dexcom has also stated that the G8 platform improves connectivity while supporting continued integration with:
- Smartphones
- Smartwatches
- Automated insulin delivery systems
- Diabetes management software[1]
Official compatibility lists will be announced closer to launch.[1]
Dexcom G8 vs. Dexcom G7
| Feature | Dexcom G7 | Dexcom G8 (Expected) |
|---|---|---|
| Sensor size | Current generation | ~50% smaller |
| Wear time | 10–15 days (model dependent) | 15 days |
| Sensing | Factory optimized | Adaptive sensing technology |
| Accuracy | Excellent | Expected improvement |
| Connectivity | Smartphone & pump integration | Enhanced platform |
| Future biosensing | Glucose | Platform designed for future multi-analyte expansion* |
*Future analyte capabilities have been discussed by Dexcom but have not been announced for the initial commercial G8 product.[1][6]
Still deciding whether to upgrade? Our Dexcom G7 comparison guide provides a side-by-side look at accuracy, wear time, connectivity, and overall performance to help you choose the right CGM.
Expected Release Date
Dexcom has not announced a commercial launch date, but current expectations are:
| Milestone | Expected Timeline |
| FDA submission | 2027 |
| Commercial launch | Late 2027 to early 2028 |
These dates are projections and remain subject to regulatory review.[3]
Should You Wait for the Dexcom G8?
If you need continuous glucose monitoring now, waiting for the G8 is generally not recommended.[4][5] The Dexcom G7 remains one of the most accurate CGMs currently available and continues to receive software updates and expanded insulin pump compatibility.
For existing G7 users, however, the G8 appears positioned as a meaningful upgrade thanks to its smaller design, adaptive sensing technology, longer wear time, and next-generation hardware platform.[1][6]
Frequently Asked Questions
References
-
MDDI. Informa Markets: Qmed+.
https://www.mddionline.com/diabetes/what-to-expect-from-the-dexcom-g8-cgm -
Dexcom Investor Relations. Corporate Overview.
https://investors.dexcom.com/ -
U.S. Securities and Exchange Commission (SEC). DexCom, Inc. Form 8-K – May 14, 2026.
https://www.sec.gov/Archives/edgar/data/1093557/000109355726000085/dxcm-20260514.htm -
American Diabetes Association. Standards of Care in Diabetes—2026.
https://diabetesjournals.org/care/issue/49/Supplement_1 -
U.S. Food & Drug Administration. Continuous Glucose Monitoring Devices.
https://www.fda.gov/medical-devices/in-vitro-diagnostics/blood-glucose-monitoring-devices -
MassDevice. Dexcom unveils next-gen G8 CGM system.
https://www.massdevice.com/dexcom-unveils-next-gen-g8-cgm/
Leave a Reply